A Phase 2 Study of IO102/IO103, Nivolumab, and Relatlimab Immunotherapy in People With Melanoma


Full Title

A Phase II study of IO102/IO103, and nivolumab-relatlimab fixed dose combination in untreated, unresectable Stage III/IV melanoma


In this study, researchers want to see how well a cancer vaccine called IO102/IO103 works in people with inoperable melanoma. Inoperable means a cancer cannot be taken out with surgery. People in this study will get IO102/IO103 with two drugs: nivolumab and relatlimab. It is hoped that combining the vaccine with these anti-cancer medications will boost the immune system to fight cancer.

Nivolumab and relatlimab both take the brakes off the immune response. They help your immune system find and kill cancer cells. They are both given intravenously (by vein).

IO102/IO103 is a vaccine with two parts. IO102 targets cells that make a protein called IDO. IO103 targets cells that make a protein called PD-L1. Both of these proteins dampen the immune response. By destroying cells that make these proteins, IO102/IO103 may help your immune system better recognize and kill cancer cells. It is given as an injection under the skin.


Who Can Join

To join this study, there are a few conditions. You must:

  • Have inoperable stage 3 or 4 melanoma.
  • Not have had treatment for inoperable stage 3 or 4 melanoma. Previous therapies must have been completed at least 6 months before getting the study treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call 646-497-9067.




Phase II (phase 2)




ClinicalTrials.gov ID